Generic Celebrex is coming

Share this article:

Teva and Pfizer have settled their Celebrex spat. Teva said in a statement Thursday that the settlement means generics of the pain med in 50mg, 100mg, 200mg and 400mg doses can hit the marketplace in December.

Last year's $3 billion in Celebrex sales represented a 7% increase in worldwide sales compared to 2012, largely supported by price increases and growth in the US.

Pfizer's fight to protect a 2015 patent extension ended last month when a court ruled a patent invalid.

Morningstar analyst Damien Conover told Reuters at the time he expected generics could cost Pfizer $1 billion in 2014.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.